Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
EpcoReal
EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)
1 other identifier
observational
700
12 countries
71
Brief Summary
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL. Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally. Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2025
Longer than P75 for all trials
71 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 12, 2025
CompletedFirst Posted
Study publicly available on registry
February 17, 2025
CompletedStudy Start
First participant enrolled
March 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2031
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2031
February 17, 2026
February 1, 2026
6.4 years
February 12, 2025
February 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of Participants Achieving Overall Response (OR)
Defined as the percentage of participants who achieve best overall response of complete response (CR) or partial response (PR) determined by Lugano criteria
Up to approximately 3 years
Study Arms (1)
Epcoritamab
Participants will receive epcoritamab as prescribed by their physician according to local label.
Eligibility Criteria
Adult participants who are being treated with epcoritamab for Diffuse Large B-Cell and Follicular Lymphoma
You may qualify if:
- Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).
- Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
- The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.
You may not qualify if:
- Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.
- Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (73)
Hospital Britanico de Buenos Aires /ID# 274419
Ciudad Autonoma de Buenos Aire, Buenos Aires, 1280, Argentina
Hospital Universitario Austral /ID# 274393
Pilar, Buenos Aires, 1629, Argentina
Instituto Alexander Fleming /ID# 277284
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1426, Argentina
Hospital Privado Universitario De Córdoba /ID# 274457
Córdoba, Córdoba Province, 5016, Argentina
Hospital Italiano de Buenos Aires /ID# 274418
Buenos Aires, 1181, Argentina
Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390
Buenos Aires, 1227, Argentina
Nepean Cancer Centre, Nepean Hospital /ID# 277782
Kingswood, New South Wales, 2747, Australia
Calvary Mater Newcastle /ID# 277783
Waratah, New South Wales, 2298, Australia
Cabrini Hospital Malvern /ID# 277780
Malvern, Victoria, 3144, Australia
Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288
Graz, Styria, 8020, Austria
Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 273266
Leoben, Styria, 8700, Austria
Algemeen Ziekenhuis klina /ID# 273405
Brasschaat, Antwerpen, 2930, Belgium
Universitair Ziekenhuis Brussel /ID# 273403
Jette, Brussels Capital, 1090, Belgium
Centre Hospitalier Epicura - Hornu /ID# 273406
Boussu, Hainaut, 7301, Belgium
Grand Hôpital De Charleroi - Notre Dame /ID# 273728
Charleroi, Hainaut, 6000, Belgium
Helora /ID# 273726
La Louvière, Hainaut, 7100, Belgium
Groupe Sante CHC - Clinique du MontLegia /ID# 273407
Liège, Liege, 4000, Belgium
Ziekenhuis Oost-Limburg, Campus St.-Jan /ID# 273729
Genk, Limburg, 3600, Belgium
Vitaz /Id# 273408
Sint-Niklaas, Oost-Vlaanderen, 9100, Belgium
AZ Oostende /ID# 273714
Ostend, West-Vlaanderen, 8400, Belgium
Umhat Sveti Ivan Rilsky /ID# 274898
Sofiya, Sofia, 1606, Bulgaria
University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 274893
Pleven, 5800, Bulgaria
Acibadem City Clinic Tokuda University Hospital EAD /ID# 273659
Sofia, 1407, Bulgaria
Specialized Hospital For Active Treatment Of Haematology Diseases /ID# 274955
Sofia, 1756, Bulgaria
Cross Cancer Institute /ID# 271504
Edmonton, Alberta, T6G 1Z2, Canada
The Moncton Hospital /ID# 277230
Moncton, New Brunswick, E1C 6Z8, Canada
Eastern Health - General Hospital /ID# 272062
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
Health Sciences North /ID# 274738
Greater Sudbury, Ontario, P3E 5J1, Canada
Kingston General Hospital /ID# 272061
Kingston, Ontario, K7L 2V7, Canada
Agios Andreas Hospital Patras /ID# 273629
Pátrai, Achaia, 26335, Greece
Evangelismos Hospital /ID# 272736
Athens, Attica, 10676, Greece
General Hospital of Athens Laiko /ID# 272758
Athens, Attica, 11527, Greece
University General Hospital Attikon /ID# 272738
Athens, Attica, 12462, Greece
Metaxa Cancer Hospital Of Piraeus /ID# 273623
Piraeus, Attica, 18537, Greece
University General Hospital of Alexandroupoli /ID# 272737
Alexandroupoli, Evros, 68100, Greece
University Hospital of Ioannina /ID# 272739
Ioannina, 45500, Greece
AHEPA University General Hospital of Thessaloniki /ID# 273633
Thessaloniki, 54636, Greece
General Hospital of Thessaloniki Hippokrateio /ID# 273635
Thessaloniki, 54642, Greece
Papageorgiou General Hospital /ID# 272735
Thessaloniki, 56429, Greece
General Hospital Of Thessaloniki G. Papanikolaou /ID# 275323
Thessaloniki, 57010, Greece
Tel Aviv Sourasky Medical Center /ID# 271615
Tel Aviv, Tel Aviv, 6423906, Israel
Hadassah Medical Center-Hebrew University /ID# 271616
Jerusalem, 91120, Israel
Rabin Medical Center. /ID# 271614
Petah Tikva, 4941492, Israel
IRCCS Ospedale San Raffaele /ID# 274789
Milan, Milano, 20132, Italy
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 274215
Naples, Napoli, 80131, Italy
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 275283
Turin, Piedmont, 10126, Italy
Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 274572
Rome, Roma, 00133, Italy
I.R.C.C.S Istituto Tumori Giovanni Paolo II /ID# 274217
Bari, 70124, Italy
Ospedale La Maddalena /ID# 274411
Palermo, 90146, Italy
Hematologica Alta Especialidad /ID# 275279
Huixquilucan de Degollado, 52787, Mexico
Centro de Especialidades Hemato-Oncologicas /ID# 275286
Mexico City, 11520, Mexico
Unidade Local de Saude de Coimbra, EPE /ID# 272720
Coimbra, 3000-075, Portugal
Unidade Local de Saúde Trás-os-Montes e Alto Douro /ID# 275404
Vila Real, 5000-185, Portugal
Complejo Hospitalario Universitario A Coruña /ID# 272040
A Coruña, A Coruna, 15006, Spain
Institut Català d'Oncologia (ICO) - Badalona /ID# 272043
Badalona, Barcelona, 08916, Spain
Hospital Universitari Parc Tauli /ID# 272044
Sabadell, Barcelona, 08208, Spain
Hospital Universitario Reina Sofia /ID# 272051
Córdoba, Cordoba, 14004, Spain
Hospital Costa del Sol /ID# 272431
Marbella, Malaga, 29603, Spain
Hospital Universitario de Navarra /ID# 272041
Pamplona, Navarre, 31008, Spain
Hospital Universitario de Valme /ID# 272050
Seville, Sevilla, 41014, Spain
Hospital de Manises /ID# 272046
Manises, Valencia, 46940, Spain
Hospital Universitario De Burgos /ID# 272066
Burgos, 09006, Spain
Hospital General Universitario Morales Meseguer /ID# 272466
Murcia, 30008, Spain
Hospital Universitario Nuestra Señora de Candelaria /ID# 272413
Santa Cruz de Tenerife, 38010, Spain
Hospital Clinico Universitario de Valladolid /ID# 272042
Valladolid, 47003, Spain
Milton Keynes Hospital /ID# 272817
Milton Keynes, Buckinghamshire, MK6 5LD, United Kingdom
Royal Cornwall Hospital /ID# 272747
Truro, Cornwall, TR1 3LQ, United Kingdom
Cheltenham General Hospital /ID# 272746
Cheltenham, Gloucestershire, GL53 7AN, United Kingdom
Queen Alexandra Hospital /ID# 272744
Portsmouth, Hampshire, PO6 3LY, United Kingdom
NHS Lanarkshire /ID# 276471
Airdrie, North Lanarkshire, ML6 0JS, United Kingdom
Nottingham City Hospital /ID# 272753
Nottingham, Nottinghamshire, NG5 1PB, United Kingdom
The Christie /ID# 272745
Manchester, M20 4BX, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 272748
Newcastle upon Tyne, NE3 3HD, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 12, 2025
First Posted
February 17, 2025
Study Start
March 28, 2025
Primary Completion (Estimated)
September 1, 2031
Study Completion (Estimated)
September 1, 2031
Last Updated
February 17, 2026
Record last verified: 2026-02